Yun Zhong
Stock Analyst at Wedbush
(0.75)
# 3,803
Out of 4,855 analysts
31
Total ratings
39.29%
Success rate
-15.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $15.04 | -0.27% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $1.92 | +316.67% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $3.07 | +944.05% | 2 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $181 → $212 | $173.24 | +22.37% | 1 | May 2, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $54.38 | +28.72% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $3.54 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.42 | +846.07% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $46.88 | +55.72% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.43 | +170.88% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.27 | +238.57% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.84 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $6.16 | +159.74% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $43.01 | +272.01% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $17.27 | +166.36% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.74 | +264.96% | 1 | May 5, 2021 |
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $15.04
Upside: -0.27%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $1.92
Upside: +316.67%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.07
Upside: +944.05%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $181 → $212
Current: $173.24
Upside: +22.37%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $54.38
Upside: +28.72%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $3.54
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.42
Upside: +846.07%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $46.88
Upside: +55.72%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.43
Upside: +170.88%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.27
Upside: +238.57%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.84
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $6.16
Upside: +159.74%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $43.01
Upside: +272.01%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $17.27
Upside: +166.36%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.74
Upside: +264.96%